Clinical Trial Update: A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 long-term safety and tolerability study of Galegenimab (FHTR2163) in geographic atrophy due to age-related macular degeneration has been terminated; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• Galegenimab (FHTR2163)

Snippet

Sponsor: Genentech, Inc. | Conditions: Macular Degeneration, Age-Related, Geographic Atrophy | Phase 2 | Status: TERMINATED | Results posted: 2023-10-16